Representative Josh Gottheimer (D-New Jersey) recently sold shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on April 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on March 7th. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.
Representative Josh Gottheimer also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of Visa NYSE: V on 3/24/2025.
- Sold $1,001 - $15,000 in shares of Spotify Technology NYSE: SPOT on 3/24/2025.
- Sold $1,001 - $15,000 in shares of Flywire NASDAQ: FLYW on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Disco OTCMKTS: DSCSY on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Diageo NYSE: DEO on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Shopify NYSE: SHOP on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk NYSE: TLK on 3/19/2025.
- Sold $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Tandem Diabetes Care NASDAQ: TNDM on 3/19/2025.
Johnson & Johnson Trading Down 0.5 %
Shares of Johnson & Johnson stock traded down $0.71 during trading on Tuesday, hitting $153.66. The stock had a trading volume of 7,861,127 shares, compared to its average volume of 7,975,028. The stock has a 50 day simple moving average of $159.38 and a 200 day simple moving average of $155.11. The company has a market capitalization of $370.29 billion, a PE ratio of 23.11, a P/E/G ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. On average, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.38%. Johnson & Johnson's payout ratio is 74.59%.
Insider Activity at Johnson & Johnson
In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on the company. Leerink Partners reduced their price objective on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a research report on Thursday, January 23rd. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Morgan Stanley raised their price target on Johnson & Johnson from $163.00 to $164.00 and gave the company an "equal weight" rating in a report on Wednesday, April 9th. Raymond James decreased their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday. Finally, Stifel Nicolaus dropped their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a research note on Thursday, January 23rd. Eight analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $171.50.
Read Our Latest Research Report on JNJ
Institutional Trading of Johnson & Johnson
Several hedge funds and other institutional investors have recently modified their holdings of JNJ. Oregon Pacific Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $949,000. Horan Securities Inc. boosted its holdings in shares of Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock worth $1,038,000 after buying an additional 90 shares during the period. Strategic Financial Concepts LLC raised its holdings in Johnson & Johnson by 57.9% in the 4th quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company's stock valued at $501,000 after acquiring an additional 1,271 shares during the period. Lord Abbett & CO. LLC acquired a new position in shares of Johnson & Johnson in the third quarter valued at approximately $69,859,000. Finally, KPP Advisory Services LLC increased its stake in shares of Johnson & Johnson by 4.7% during the fourth quarter. KPP Advisory Services LLC now owns 11,492 shares of the company's stock worth $1,662,000 after purchasing an additional 515 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.
About Representative Gottheimer
Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.
Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2026 election.
Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.
Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
